heartandhealth

Heart and Health

1 Years ago

Cardiac toxicity risk factors identified with relapsed multiple myeloma therapy

More than half of patients with relapsed multiple myeloma treated with carfilzomib experienced cardiac issues during treatment, according to a multi-institutional study. The study recommends that patients undergo a detailed cardiovascular history before being prescribed carfilzomib and then be monitored with natriuretic peptide testing, an indicator for heart failure.

  • 0 Likes

  • 0 Comments